Overview

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

Status:
Completed
Trial end date:
2019-08-13
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2, double-blind (study participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in participants with Acute Ischemic Stroke (AIS).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.